[Selection of oral antidiabetic drugs].
Iwamoto
Yasuhiko
Y
Diabetes Center, Tokyo Women's Medical University.
D020909:Acarbose; D000284:Administration, Oral; D001645:Biguanides; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control; D004791:Enzyme Inhibitors; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000494:pharmacology; D007211:Indoles; D054833:Isoindoles; D012306:Risk; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones
D001645:Biguanides; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007211:Indoles; D054833:Isoindoles; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione; C087255:mitiglinide; D020909:Acarbose